We are excited to share a study from our lab comparing macrophage immune checkpoints in cancer! This work was led by Juliet Allen and Anna Meglan and describes novel strategies to engage macrophages as effector cells for human cancers.

We are excited to share a study from our lab describing a novel strategy to rapidly produce, test, and validate bispecific antibodies for lymphoma! This work was led by Juliano Ribeiro and Carlota Pagès-Geli in collaboration with the lab of Marta Crespo at Vall d'Hebron Institute of Oncology (VHIO).

Research from the Weiskopf lab was presented by Dr. Weiskopf at the James P. Allison Institute Next Gen Colloquium in Houston, TX.

Research from the Weiskopf Lab is presented by Carlota Pagès-Geli at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; October 23-25, 2024; Barcelona, Spain.

Research from the Weiskopf Lab is presented by Anna Meglan at the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; October 18-21, 2024; Boston, MA.

Dr. Weiskopf is featured as a guest on The Immunology Podcast to discuss strategies for targeting myeloid cells in cancer.

Research from the Weiskopf Lab is presented by Juliano Ribeiro at the Fourth AACR International Meeting on Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application; June 19-22, 2024; Philadelphia, PA.

Weiskopf Lab research on the combination of targeted therapies and macrophage immunotherapies is highlighted by Whitehead Institute.

Research from the Weiskopf lab is published in the Journal of Clinical Investigation. This study was led by first authors Kyle Vaccaro and Juliet Allen.

A profile of Dr. Asaf Maoz, a postdoctoral scholar in the Weiskopf lab, is featured on Whitehead Institute’s website. Dr. Maoz is studying the effects of cytokines on the immune response against cancer.

Research performed by the Weiskopf lab in collaboration with the lab of Dr. Robert Weinberg was published in Cell Reports. This study was led by first author Vaishnavi Phadnis from the Weinberg lab.

Solu Therapeutics is launched with Dr. Weiskopf as a scientific co-founder.

Dr. Weiskopf is awarded a Catalyst Award by the American Lung Association to discover more effective ways to treat KRAS mutant lung cancer.

Dr. Weiskopf serves as conference chairman and speaker at the 4th Macrophage-directed Therapies Summit in Boston, MA.

New biotech startup, DEM BioPharma, launches with $70 million in financing as a spinout from the Weiskopf laboratory.

Dr. Weiskopf is awarded a Career Development Award from the Department of Defense.

Dr. Weiskopf participates as a speaker in the Longwood Healthcare Leaders 2022 MIT Webconference.

Dr. Weiskopf is awarded the inaugural 2022 AACR-AstraZeneca Career Development Award for Physician-Scientists, in Honor of José Baselga. The grant funding will be used to support unbiased discovery of macrophage-directed immunotherapies for cancer.

The Weiskopf laboratory presents research on macrophage immunotherapies for lung cancer at the 2022 American Cancer Society Annual Meeting in New Orleans, LA.

Clinician-scientist Kipp Weiskopf appointed as a Valhalla Fellow at Whitehead Institute.